Technology
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready To Meet Demand?
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ramp up production enough.
By: wsj
- Nov 18 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS